高糖皮质激素受体表达预测卵巢癌无进展生存期缩短
研究纳入481例卵巢癌患者和4例良性病变患者,用组织微阵列免疫组化评估糖皮质激素受体(GR)表达,高GR定义为>1%肿瘤细胞强度2+或3+。在341例接受初始肿瘤减灭术加辅助化疗的患者中,133例(39.0%)高表达GR;高GR者中位无进展生存期(PFS)为20.4个月,低GR者为36.0个月(HR=1.66,95%CI 1.29-2.14,p<0.001),多因素分析中GR为PFS独立预后因素,总生存期(OS)与GR状态无关。
要点
- 高GR表达与浆液性肿瘤、高级别肿瘤及晚期肿瘤相关(p分别<0.001、<0.001、0.037)。
- 高GR者中位PFS为20.4个月,低GR者为36.0个月(HR=1.66,95%CI 1.29-2.14,p<0.001)。
- 多因素分析中GR为PFS独立预后因素,OS与GR状态无关。
核心结论
- 这些数据提示高GR表达与不良预后相关,并支持调控GR活性联合化疗可能改善结局的假说。
研究设计与样本
- 研究采用组织微阵列免疫组化评估481例卵巢癌患者和4例良性病变患者的肿瘤GR表达。
- 低GR定义为肿瘤细胞强度0或1+,高GR定义为>1%肿瘤细胞强度2+或3+。
主要发现
- 在341例接受初始肿瘤减灭术加辅助化疗的患者中,133例(39.0%)肿瘤高表达GR蛋白。
- 高GR表达在浆液性肿瘤(p<0.001)、高级别肿瘤(p<0.001)和晚期肿瘤(p=0.037)中更常见。
- 高GR者中位PFS为20.4个月,低GR者为36.0个月(HR=1.66,95%CI 1.29-2.14,p<0.001)。
- 多因素分析中GR仍为PFS的独立预后因素。
- OS与GR状态无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association of tumor glucocorticoid receptor (GR) expression and patient outcome in ovarian cancer. METHODS: GR expression was evaluated by immunohistochemistry using tissue microarrays of specimens from 481 patients with ovarian cancer and 4 patients with benign conditions. Low GR expression was defined as an intensity of 0 or 1+ and high GR as 2+ or 3+ in >1% of tumor cells. Analyses were performed to evaluate the relationship of GR expression with clinical characteristics, progression-free survival (PFS) and overall survival (OS). RESULTS: GR protein was highly expressed in 133 of 341 (39.0%) tumors from patients who underwent upfront cytoreduction surgery followed by adjuvant chemotherapy. High GR expression was more common in serous tumors (p<0.001), high grade tumors (p<0.001), and advanced stage tumors (p=0.037). Median PFS was significantly decreased in cases with high GR (20.4months) compared to those with low GR (36.0months, HR=1.66, 95% CI 1.29-2.14, p<0.001). GR remained an independent prognostic factor for PFS in multivariate analysis. OS was not associated with GR status. CONCLUSIONS: These data suggest that high GR expression correlates with poor prognosis and support the hypothesis that modulating GR activity in combination with chemotherapy may improve outcomes.
引用
- Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017. PMID: 28456378. doi:10.1016/j.ygyno.2017.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。